Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery

Approximately 20% of all non-small cell lung cancer (NSCLC) is stage IIIA-N2 (1). Those patients are heterogeneous in terms of disease extent and survival. Treatment options included induction chemotherapy or concurrent chemoradiotherapy (CCRT) followed by surgery, or definitive CCRT (2-7). The optimal strategy for IIIA-N2 NSCLC remains controversial and no treatment is clearly recommended (8,9)